Trends in Usage and Payments for Glucagon‐Like Peptide‐1 Receptor Agonists in the United States, 2017 to 2022: A Nationally Representative Repeated Cross‐Sectional Study

lucagon-like peptide-1 receptor agonists (GLP-1RAs) are effective therapies for glucose-lowering and weight management.A growing number of therapies within this drug class are now available.1,2 Despite the rapid uptake of GLP-1RAs, differences in use and costs across GLP-1RA subtypes and by indication are not known.This study aims to investigate how usage patterns and associated payments may differ across GLP-1RAs and by diabetes status.This study was considered exempt by Northwestern University's institutional review board due to the use of publicly available deidentified data.We analyzed data from the Medical Expenditure Panel Survey (MEPS), a nationally representative repeated cross-sectional sample of US adults.